Quest Partners LLC Purchases New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Quest Partners LLC acquired a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,630 shares of the biotechnology company’s stock, valued at approximately $29,000.

Several other institutional investors and hedge funds also recently modified their holdings of ADMA. Viewpoint Capital Management LLC boosted its stake in shares of ADMA Biologics by 18.6% in the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 2,416 shares during the period. Arizona State Retirement System lifted its holdings in ADMA Biologics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 61,641 shares of the biotechnology company’s stock worth $689,000 after buying an additional 2,645 shares in the last quarter. Eagle Asset Management Inc. boosted its position in ADMA Biologics by 20.2% in the 4th quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 4,367 shares during the last quarter. CWM LLC grew its stake in shares of ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 4,367 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of ADMA Biologics by 9.2% during the first quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 4,570 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $19.98 on Friday. The stock has a market capitalization of $4.63 billion, a price-to-earnings ratio of -999.00 and a beta of 0.61. ADMA Biologics, Inc. has a one year low of $3.06 and a one year high of $20.16. The company’s 50-day simple moving average is $15.77 and its 200-day simple moving average is $10.93. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. The firm had revenue of $107.20 million for the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. ADMA Biologics’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.02) earnings per share. Equities analysts anticipate that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ADMA has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday. HC Wainwright upped their target price on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Mizuho increased their target price on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, ADMA Biologics currently has a consensus rating of “Buy” and an average price target of $15.50.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the transaction, the director now owns 241,441 shares of the company’s stock, valued at $4,408,712.66. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 466,900 shares of company stock valued at $8,224,121. Corporate insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.